US Edition3 Articles
3 Articles
RNAi-based drug design: considerations and future directions
More than 25 years after its discovery, the post-transcriptional gene regulation mechanism termed RNAi is now transforming pharmaceutical development, proved by the recent FDA approval of multiple small interfering RNA (siRNA) drugs that target the liver. Synthetic siRNAs that trigger RNAi have the potential to specifically silence virtually any therapeutic target with unprecedented potency and durability. Bringing this innovative class of medic…
A novel and innovative therapeutic approach Since its creation, EPICS has focused its efforts on the discovery and development of small molecules in the emerging field of RNA epigenetics. This promising new approach opens the way to more targeted and personalized cancer treatments. Its main candidate, EP102, is a METTL3 enzyme inhibitor, whose overexpression is observed in many cancers. Early preclinical tests show powerful effects on inhibition…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium